The American Cancer Society has released updated guidance on hormone replacement therapy (HRT) and cancer risk, clarifying which patients face elevated risks and which can safely pursue treatment for menopausal symptoms. The 2026 recommendations reflect analysis of over 15 years of follow-up data from major studies, providing clearer risk stratification than previous guidelines.
According to the new guidance, combined estrogen-progestin therapy remains associated with a small increased risk of breast cancer—approximately one additional case per 1,000 women using HRT for five years. However, the data shows this risk diminishes rapidly after discontinuation, typically returning to baseline within two years. Estrogen-only therapy, used by women who have had hysterectomies, shows no increased breast cancer risk and may actually offer modest protection. The guidance also addresses endometrial, ovarian, and colorectal cancer risks, noting that proper progestin use eliminates elevated endometrial cancer concerns.
These updated recommendations come at a critical time, as recent years have seen renewed interest in HRT following decades of hesitation stemming from the 2002 Women’s Health Initiative findings. Many physicians had avoided prescribing HRT altogether, leaving countless women to suffer through debilitating menopausal symptoms unnecessarily. The medical community now recognizes that the original study’s risks were overstated for many patient populations, particularly younger women beginning HRT near menopause onset.
For patients considering HRT, the American Cancer Society emphasizes individualized risk assessment. Women with personal or strong family histories of breast cancer should discuss alternatives with their healthcare providers, while those with severe menopausal symptoms and no significant risk factors can feel more confident about short-term HRT use. The organization recommends using the lowest effective dose for the shortest necessary duration, with annual reassessment of the benefit-risk profile.
